South Korea Orthognathic Craniomaxillofacial (Cmf) Devices Market Forecast 2025-2032

The South Korea orthognathic craniomaxillofacial devices market is evaluated to grow with a CAGR of 6.32% during the forecasting period of 2025-2032. The market was valued at $26.19 million in 2024 and is expected to reach a revenue of $61.49 million by 2032.

According to industry sources, South Korea’s healthcare sector continues to experience substantial growth. Aligning with this, in 2023, the healthcare expenditure reached approximately $4,600 per capita, and total medical spending amounted to 112.4 trillion South Korean Won. This accounts for 9.3% of the nation’s GDP, reflecting the country’s prioritization of healthcare advancements.

MARKET INSIGHTS

Further, these investments have facilitated the adoption of specialized medical technologies, including orthognathic craniomaxillofacial (CMF) devices and craniomaxillofacial surgical equipment, which are integral to reconstructive and corrective jaw surgeries.

A notable factor contributing to the growth of the CMF devices industry is the affordability of jaw surgery in South Korea. The cost of such procedures typically ranges between $5,000 and $20,000, depending on the complexity and extent of the surgery, making it a cost-effective option compared to other countries.

This affordability, coupled with South Korea’s reputation for advanced surgical expertise, has attracted a significant number of international patients seeking treatments for various conditions. These include malocclusion, facial asymmetry, and trauma-related deformities.

In 2023 alone, more than 606,000 international patients visited South Korea, according to the Ministry of Health and Welfare, further cementing its status as a leading medical tourism hub in Asia. South Korea’s well-developed healthcare infrastructure and adoption of cutting-edge technologies further support the growth of the CMF medical devices market.

Digital surgical planning and the utilization of 3D-printed implants are increasingly becoming standard practices, reflecting the sector’s focus on precision and patient-specific solutions. Additionally, the rising interest in facial aesthetic procedures, particularly among medical tourists and domestic patients, has augmented the demand for orthognathic surgeries and related medical devices.

SEGMENTATION ANALYSIS

The South Korea orthognathic craniomaxillofacial devices market is segmented into product type, material, and end-user. The end-user segment is further classified into hospitals, specialized clinics, ambulatory surgery centers, and other end-users.

Ambulatory surgery centers (ASCs) play an increasingly significant role in the orthognathic cranio-maxillofacial (CMF) devices market as a key end-user. These centers are designed to handle less complex orthognathic procedures that do not necessitate extended hospital stays, such as corrective jaw surgeries for minor malocclusions or facial asymmetries.

ASCs provide a streamlined and patient-centric approach, making them an appealing alternative to traditional hospital settings for many individuals. One of the primary advantages of ASCs is their cost-effectiveness. These facilities are able to perform surgeries at a lower overall cost compared to hospitals, primarily due to their focused infrastructure and efficient operational models.

In addition to cost benefits, ASCs are valued for their emphasis on convenience and shorter recovery times. Patients undergoing orthognathic procedures in these centers typically experience less time in a clinical setting, as ASCs are designed to expedite pre-and post-operative care. This efficiency has made ASCs particularly popular among patients seeking a quicker return to daily activities without compromising the quality of surgical care.

COMPETITIVE INSIGHTS

Some of the top players operating in South Korea orthognathic craniomaxillofacial (CMF) devices market include DePuSynthes (Johnson & Johnson Inc), KLS Martin, Medartis AG, etc.

Medartis AG is a medical device manufacturer that focuses on the development and production of implants for osteosynthesis. Established in 1997, the company is headquartered in Switzerland and operates across North America, Europe, Asia-Pacific, Latin America, and the Middle East.

Medartis’ implant solutions are primarily designed for use in cranio-maxillofacial surgery and the treatment of upper and lower extremities. Its product portfolio includes specialized screws, plates, and related devices aimed at supporting surgical precision and patient care.

Please Note: Report includes PDF + Excel